KZRNCMHealthcare·Biotechnology#414 in industry

Kezar Life Sciences, Inc.

Reports in 15d· 2026-05-12

+17.0% · 90d

$7.29

-0.04 (-0.55%)

After-Hours $7.29(+0.00)

News

(1)

March 2026

Mar 30, 20260 months ago8-KHealthcare

Kezar Life Sciences, Inc. — 8-K Filing

KZRKezar Life Sciences, Inc.

# 🧾 What This Document Is This is an **SEC Form 8-K filing** from Kezar Life Sciences. It contains the official legal contracts for a major corporate event: **Kezar is being acquired by Aurinia Pharma.** Think of it like the final paperwork you sign when selling a house. It doesn't just say "we'r

Read summaryView on SEC EDGAR

Key Data

Market Cap$53.7M

Open$7.33

Prev Close$7.33

Day Range$7.26 – $7.45

52W Range$3.53 – $7.55

Volume39,900

P/E (TTM)—

EPS$-7.66

Dividend Yield—

Beta0.43

Price Target$7.00(-4.0%)

Next Earnings2026-05-12(15d)

Analyst Ratings

Hold2 analysts

Buy 0Hold 2Sell 0

About

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Healthcare · Biotechnology

9 employees

www.kezarlifesciences.com